Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Loeber R, Michaelson E, Fang Q, Campbell C, Pegg AE, Tretyakova N: Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. Chem Res Toxicol. 2008 Apr;21(4):787-95. Epub 2008 Feb 14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18324787 # Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP: Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair (Amst). 2006 Aug 13;5(8):972-85. Epub 2006 Jun 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16781199 # Moscow JA, Swanson CA, Cowan KH: Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer. 1993 Oct;68(4):732-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8398701 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - 1.5 (±0.83) hours (en)
|
http://linked.open...ugbank/indication
| - For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases (primarily at the N-7 position of guanine and to a lesser extent, at the N-3 position of adenine), forming monoadducts and resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...y/drugbank/patent
| |
http://linked.open...outeOfElimination
| - The 24-hour urinary excretion of parent drug in these patients was 10% ± 4.5%, suggesting that renal clearance is not a major route of elimination of parent drug. (en)
|
http://linked.open.../drugbank/synonym
| - L-PAM (en)
- L-Phenylalanine mustard (en)
- L-Sarcolysine (en)
- Phenylalanine mustard (en)
- Phenylalanine nitrogen mustard (en)
- 3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine (en)
- 3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine (en)
- 4-(Bis(2-chloroethyl)amino)-L-phenylalanine (en)
- L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine (en)
- Melfalano (en)
- Melphalanum (en)
- P-Di-(2-chloroethyl)amino-L-phenylalanine (en)
- P-L-Sarcolysin (en)
- P-N-Bis(2-chloroethyl)amino-L-phenylalanine (en)
- p-Bis(beta-chloroethyl)aminophenylalanine (en)
- p-N,N-bis(2-chloroethyl)amino-L-phenylalanine (en)
|
http://linked.open...drugbank/toxicity
| - Vomiting, ulceration of the mouth, diarrhea, and hemorrhage of the gastrointestinal tract; The principal toxic effect is bone marrow suppression. LD<sub>50</sub>=11.2 mg/kg (orally in rat) (en)
|
http://linked.open...umeOfDistribution
| |
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Take on an empty stomach. Food decreases bioavailabilty by approximately 30%. Increase liquid intake. (en)
|
http://linked.open...nk/proteinBinding
| - Moderate to high (60 to 90%), primarily to albumin and, to a lesser extent, alpha 1-acid glycoprotein. 30% is irreversibly bound. (en)
|
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - "DrugSyn.org":http://www.drugsyn.org/Melphalan.htm (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Incomplete, variable, 25-89% post oral dose (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |